Vivek Subbiah: Mark your calendars if you are attending the NCI AACR EORTC 2023- The triple meeting in Boston, Oct 11-15.

Vivek Subbiah shared on LinkedIn:

“Mark your calendars if you are attending the NCI AACR EORTC 2023- The triple meeting in Boston, Oct 11-15.

Delighted to be discussing about the ‘Future of Tissue-Agnostic Drug Development’ with an amazing panel of speakers & delivering a lecture on.

‘Unleashing the power of precision: Exploring pan-targets, anti-body drug conjugates and beyond for novel tumor-agnostic drug development’.

Oct 12th 4.00 pm to 5.40 pm Level 3, Ballroom AB.”

Source: Vivek Subbiah/LinkedIn

Vivek Subbiah is the Chief of Early-Phase Drug Development at the  Sarah Cannon Research Institute. He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Subbiah’s research interests include drug development in rare cancers, immunotherapy, and radiopharmaceuticals.